ReviewActa neuropsychiatrica2026
The effects of psychedelics on attention deficit and hyperactivity disorder - a systematic review.
Review in Acta neuropsychiatrica, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesAttention deficit and hyperactivity disorder (ADHD) is a prevalent neuropsychiatric disorder (Drechsler et al., 2020). Recently, psychedelics have become of interest regarding developing treatment options for ADHD. The aim of this systematic review is to find all studies from the APA PsychInfo and MEDLINE databases, where psychedelics have been used for ADHD and assess whether further clinical studies are warranted.
methodsAPA PsychInfo and MEDLINE were searched on the 20th of August 2025 for studies discussing ADHD and lysergic acid diethylamide (LSD) or psilocybin or dimethyltryptamine (DMT) or mescaline or phencyclidine or 3,4-methylenedioxymethamphetamine (MDMA) or ketamine. Primary research articles in English where the effects of the psychedelics mentioned on ADHD in humans were included.
results
conclusionsThere is not sufficient evidence to give recommendations on psychedelic use for ADHD. In addition, it is not known whether patients, whose depressive symptoms have responded positively to ketamine, have also had ADHD. Also, no research was found on how psychedelics affect patient subgroups with different etiopathology causing their symptoms. Although only six studies filled the inclusion criteria, they bring out valuable implications for further research.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.